0.06
-0.0139(-19.86%)
Currency In USD
| Previous Close | 0.07 |
| Open | 0.07 |
| Day High | 0.07 |
| Day Low | 0.06 |
| 52-Week High | 0.07 |
| 52-Week Low | 0.06 |
| Volume | 23,629 |
| Average Volume | 39,473.78 |
| Market Cap | 16.4M |
| PE | -0.03 |
| EPS | -1.73 |
| Moving Average 50 Days | 0.08 |
| Moving Average 200 Days | 0.05 |
| Change | -0.01 |
Cingulate Provides Management Team Update
GlobeNewswire Inc.
Aug 15, 2025 1:00 PM GMT
Jennifer Callahan, Chief Financial Officer, appointed Interim CEO Board member, Jay Roberts appointed Executive Chairman KANSAS CITY, Kan., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CING) The Board of Directors of Cingulate Inc. (“Cingulate”) ann
Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301
GlobeNewswire Inc.
Aug 06, 2025 12:45 PM GMT
Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patientsKANSAS CITY, Kan., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical c
Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301
GlobeNewswire Inc.
Jul 29, 2025 12:00 PM GMT
PDUFA Fee Waiver comes Days before Planned Submission of New Drug ApplicationKANSAS CITY, Kan., July 29, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) d